戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 construction of an effective vaccine against giardiasis.
2  rate of quinacrine in those with persistent giardiasis.
3 tribute to diarrheal disease associated with giardiasis.
4 tance, no human vaccine is available against giardiasis.
5 ns with giardiasis and 19663 persons without giardiasis.
6  intranasal immunization in rodent models of giardiasis.
7 nts pathological CD8(+) T cell activation in giardiasis.
8 moebiasis equals or exceeds the incidence of giardiasis.
9 s and immune responses in the mouse model of giardiasis.
10 affected disaccharidase levels during murine giardiasis.
11 ith perceived food intolerance 3 years after giardiasis.
12 ates, and their efficacy in a mouse model of giardiasis.
13  ineffectiveness in drug resistance cases of giardiasis.
14 atic; all 3 were subsequently diagnosed with giardiasis.
15 n a fast food restaurant, was diagnosed with giardiasis.
16  the absence of fever and was diagnosed with giardiasis.
17  all, 1262 patients had laboratory confirmed giardiasis.
18 ding of the clinical variation seen in human giardiasis.
19 targets for developing new therapies against giardiasis.
20 ta-giardins, that are also detected in human giardiasis.
21 reatment of cryptosporidiosis and refractory giardiasis.
22 proach to the epidemiologic investigation of giardiasis.
23 a low cure rate in nitroimidazole-refractory giardiasis.
24  of quinacrine for nitroimidazole-refractory giardiasis.
25 n effective against metronidazole-refractory giardiasis.
26  in particular relevant for chronic cases of giardiasis.
27 ily for 5 days) in nitroimidazole-refractory giardiasis.
28 e group are important to the epidemiology of giardiasis.
29 tigue has previously been reported following giardiasis after a large waterborne outbreak in Bergen,
30 zole was prescribed to 22 dogs for suspected giardiasis after exhibiting gastrointestinal symptoms su
31 dence regarding the management of refractory giardiasis after treatment with nitroimidazoles.
32 d natural course of fatigue five years after giardiasis among patients who reported chronic fatigue t
33 he matched cohort included 3935 persons with giardiasis and 19663 persons without giardiasis.
34                           Cryptosporidiosis, giardiasis and microsporidiosis are serious human diseas
35 ghlight recent work focused on the impact of giardiasis and the mechanisms that contribute to the var
36                                      Dengue, giardiasis, and insect bites had high proportionate morb
37 oridiosis and the diagnosis of amebiasis and giardiasis, and some new leads on the treatment of crypt
38                        Cryptosporidiosis and giardiasis are major public health concerns.
39 eton is a promising drug target for treating giardiasis, as we predict drugs that interfere with the
40                                In refractory giardiasis, assemblage A and B were found responsible in
41  Almost 20% of patients presented persistent giardiasis, belonging to both assemblages A and B, after
42 icrobiota may explain observed variations in giardiasis between hosts with respect to host pathology,
43 ctive treatment in nitroimidazole-refractory giardiasis, but patients should be cautioned on the low
44                                              Giardiasis care infrequently follows all aspects of clin
45 ctive was to describe the epidemiology of US giardiasis cases from 1995 through 2016 using National N
46                    Nitroimidazole-refractory giardiasis cases, defined as microbiologically (microsco
47  were quantified in 28 patients with chronic giardiasis (CG), 66 patients with persistent abdominal s
48 vage pathway, is a potential target for anti-giardiasis chemotherapy.
49                                              Giardiasis could be an ecological disease, and the obser
50         We examined the relationship between giardiasis diagnosis and irritable bowel syndrome (IBS)
51                      Persons with at least 1 giardiasis diagnosis were individually matched on age gr
52 ment length in months to 5 persons without a giardiasis diagnosis.
53                 We investigated sequences of giardiasis diagnostic and treatment events using MarketS
54 ng all patients who had laboratory confirmed giardiasis during the Bergen outbreak (n=1252) were invi
55                                        After giardiasis enteritis at least 5% developed clinical char
56 ducation after a large community outbreak of giardiasis enteritis in the city of Bergen, Norway were
57                                              Giardiasis failing nitroimidazole first-line treatment i
58 ic filariasis (Brugia,Wuchereria bancrofti), giardiasis (Giardia), toxoplasmosis (Toxoplasma gondii),
59                        In the United States, giardiasis has been variably reportable since 1992 and w
60 study estimates the proportion of persistent giardiasis in 3 hospitals in Barcelona, describes associ
61 nflicting results, placing endemic pediatric giardiasis in a state of equipoise.
62             The annual incidence of reported giardiasis in the United States decreased across all age
63 udinal cohort of 2995 persons diagnosed with giardiasis (International Classification of Diseases, Ni
64  incidence of IBS was higher in persons with giardiasis (IR = 37.7/1000 person-years vs 4.4/1000 pers
65                                              Giardiasis is a diarrheal disease caused by the unicellu
66                                              Giardiasis is a disease caused by the protist Giardia la
67                                              Giardiasis is the most common intestinal parasitic disea
68      Giardia lamblia, the causative agent of giardiasis, lacks de novo purine biosynthesis and relies
69  malnutrition to demonstrate that persistent giardiasis leads to epithelial cell apoptosis and crypt
70  and were more effective than Mz in a murine giardiasis model.
71  an effectiveness rate of 100% in refractory giardiasis (n = 13; 95% confidence interval = 75-100).
72 s is spreading, new strategies for combating giardiasis need to be developed.
73 inal complaints has been reported after some giardiasis outbreaks.
74  .007) and anorexia (P = .02), with previous giardiasis (P = .03), and with previous antibiotic (P =
75 uture research on risk factors for IBS among giardiasis patients and the pathophysiology of postinfec
76 e mechanisms of pathogenesis associated with giardiasis remain unclear, as the parasite neither produ
77 blia, the protozoan parasite responsible for giardiasis, requires purine salvage from its host for RN
78  protozoa (amebiasis, cryptosporidiosis, and giardiasis), rotavirus, astrovirus, and enterotoxigenic
79 ng 724 individuals with laboratory confirmed giardiasis six years earlier, and 847 controls matched b
80             Here we show in murine models of giardiasis that small-intestinal hypermotility occurs in
81                                              Giardiasis, the most common enteric parasitic infection
82 lude that CD8(+) T cells become activated in giardiasis through an antibiotic-sensitive process and c
83 ational study was conducted in patients with giardiasis treated with nitroimidazoles.
84                                   Refractory giardiasis was associated with malaise (P = .007) and an
85 in the period from three to five years after giardiasis was found.
86                                  Concomitant giardiasis was neither a risk factor nor protective.
87                    Nitroimidazole-refractory giardiasis was primarily seen in travelers returning fro
88                       Using a mouse model of giardiasis, we examined the role of host immunity and pa
89 lates from a previously reported epidemic of giardiasis were accurately classified by this technique,
90 nfectious fatigue after laboratory confirmed giardiasis were diagnosed with CFS.
91 surance database, individuals diagnosed with giardiasis were more likely to have a subsequent IBS dia
92                        Those with persistent giardiasis were provided quinacrine.
93 e (30.8%) in the exposed group 6 years after giardiasis were significantly elevated compared with con
94  12 with symptoms consistent with intestinal giardiasis) were determined to be positive for G. lambli
95               The patient was diagnosed with giardiasis, which led to examination of her mother, fath
96  factors of populations with higher rates of giardiasis will support prevention and control efforts.
97 tive treatment for nitroimidazole-refractory giardiasis with good tolerability.
98 eople are estimated to have acute or chronic giardiasis, with infection rates approaching 90% in area